TB vaccine trial is step forward though results 'not what hoped' TB vaccine trial is step forward though results 'not pancreatic cancer epidemiology hoped' Research 5 Pancreatic cancer epidemiology A new vaccine against tuberculosis developed at Oxford University — the TB vaccine most advanced in clinical trials — has been found not to offer extra protection against the disease in babies previously vaccinated with BCG.
Link to full story here © Oxford University The clinical trial was the first to evaluate the ability of a new TB vaccine to prevent the disease since BCG, the 90 year-old vaccine that is familiar to many and is used extensively throughout the world.
The study involved almost 2, babies in South Africa and the findings are published in the medical journal The Lancet. Professor Helen McShane, who first developed the MVA85A vaccine 15 years ago at Oxford University's Jenner Institute and is senior author on the Lancet paper, says pancreatic cancer epidemiology the disappointing results, getting to this point marks a step forward for the field and there is much to be learned from the results.
Ann Ital Chir ; The purpose of our study was to analyse the immediate and remote results obtained after MOR and to identify potential factors that might influence the outcome. We excluded patients with hepatic metastatic tumors and those who needed pelvic exenteration. Pancreatic cancer epidemiology andin our service, have been treated with MOR patients, being included in our study. We analysed morbidity, mortality and survival after MOR and the factors that could have influenced the postoperative course.